RAPT Therapeutics Inc. (NASDAQ:RAPT)’s traded shares stood at 1.03 million during the last session, with the company’s beta value hitting 0.47. At the close of trading, the stock’s price was $18.94, to imply a decrease of -1.81% or -$0.35 in intraday trading. The RAPT share’s 52-week high remains $32.45, putting it -71.33% down since that peak but still an impressive 47.99% since price per share fell to its 52-week low of $9.85. The company has a valuation of $764.04M, with an average of 0.81 million shares in intraday trading volume over the past 10 days and average of 471.21K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for RAPT Therapeutics Inc. (RAPT), translating to a mean rating of 1.80. Of 9 analyst(s) looking at the stock, 0 analyst(s) give RAPT a Sell rating. 1 of those analysts rate the stock as Overweight while 0 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.66.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
RAPT Therapeutics Inc. (NASDAQ:RAPT) trade information
After registering a -1.81% downside in the last session, RAPT Therapeutics Inc. (RAPT) has traded red over the past five days. The stock hit a weekly high of 26.76 this Friday, 03/17/23, dropping -1.81% in its intraday price action. The 5-day price performance for the stock is -23.32%, and -33.87% over 30 days. With these gigs, the year-to-date price performance is -4.34%. Short interest in RAPT Therapeutics Inc. (NASDAQ:RAPT) saw shorts transact 3.2 million shares and set a 6.92 days time to cover.
Analysts on Wall Street suggest a consensus price target of $40.89, implying an increase of 53.68% to the stock’s current value. The extremes give us $23.00 and $48.00 for target low and target high price respectively. As such, RAPT has been trading -153.43% off suggested target high and -21.44% from its likely low.
RAPT Therapeutics Inc. (RAPT) estimates and forecasts
Looking at statistics comparing RAPT Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. RAPT Therapeutics Inc. (RAPT) shares are -28.61% down over the last 6 months, with its year-to-date growth rate lower than industry average at -10.85% against 9.60%. Revenue is forecast to shrink -8.20% this quarter before falling -5.80% for the next one. The rating firms project that company’s revenue will shrink -57.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is $220k. Earnings reports from the last fiscal year show that sales brought in $756k and $641k respectively in the corresponding quarters.
RAPT Therapeutics Inc. has its next earnings report out between May 09 and May 15. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. RAPT Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
RAPT Therapeutics Inc. (NASDAQ:RAPT)’s Major holders
RAPT Therapeutics Inc. insiders hold 1.84% of total outstanding shares, with institutional holders owning 89.82% of the shares at 91.51% float percentage. In total, 89.82% institutions holds shares in the company, led by FMR, LLC. As of Sep 29, 2022, the company held over 3.58 million shares (or 11.96% of shares), all amounting to roughly $86.05 million.
The next major institution holding the largest number of shares is Price (T.Rowe) Associates Inc with 3.08 million shares, or about 10.30% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $74.1 million.
We also have Price (T.Rowe) New Horizons Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF as the top two Mutual Funds with the largest holdings of the RAPT Therapeutics Inc. (RAPT) shares. Going by data provided on Sep 29, 2022, Price (T.Rowe) New Horizons Fund holds roughly 1.64 million shares. This is just over 5.49% of the total shares, with a market valuation of $39.49 million. Data from the same date shows that the other fund manager holds a little less at 1.4 million, or 4.67% of the shares, all valued at about 27.68 million.